Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04638634




Registration number
NCT04638634
Ethics application status
Date submitted
19/11/2020
Date registered
20/11/2020
Date last updated
10/12/2021

Titles & IDs
Public title
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
Scientific title
A Single Center, Phase 1, Single-Ascending Dose, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
Secondary ID [1] 0 0
CSL760_1001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Coronavirus Disease 2019 (COVID-19) 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - CSL760

Experimental: CSL760 (low dose) - Administered as an intravenous infusion

Experimental: CSL760 (high dose) - Administered as an intravenous infusion


Other interventions: CSL760
An Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Total immunoglobulin (IgG) concentration of CSL760
Timepoint [1] 0 0
At 0,0.5,1,2,6,12,24, and 48 hours, and 7,14,28,49, and 91 days after end of IV infusion
Primary outcome [2] 0 0
Maximum concentration (Cmax) of CSL760
Timepoint [2] 0 0
Up to 91 days after end of IV infusion
Primary outcome [3] 0 0
Time of Cmax (tmax) of CSL760
Timepoint [3] 0 0
Up to 91 days after end of IV infusion
Primary outcome [4] 0 0
Area under the concentration-time curve (AUC) from time 0 to the last measurable concentration (AUC0-last) of CSL760
Timepoint [4] 0 0
Up to 91 days after end of IV infusion
Secondary outcome [1] 0 0
Number of subjects with Treatment-emergent adverse events (TEAEs)
Timepoint [1] 0 0
From start of infusion up to 91 days
Secondary outcome [2] 0 0
Percent of subjects with TEAEs
Timepoint [2] 0 0
From start of infusion up to 91 days
Secondary outcome [3] 0 0
Number of subjects with Serious adverse events (SAEs)
Timepoint [3] 0 0
From start of infusion up to 91 days
Secondary outcome [4] 0 0
Percent of subjects with SAEs
Timepoint [4] 0 0
From start of infusion up to 91 days
Secondary outcome [5] 0 0
Number of subjects with Clinically significant laboratory abnormalities that are reported as adverse events (AEs)
Timepoint [5] 0 0
From start of infusion up to 91 days
Secondary outcome [6] 0 0
Percent of subjects with Clinically significant laboratory abnormalities that are reported as AEs
Timepoint [6] 0 0
From start of infusion up to 91 days

Eligibility
Key inclusion criteria
- Male or female 18 to 65 years of age

- Female subjects must be postmenopausal or have a negative pregnancy test

- Body weight in the range of = 50 kg and = 100 kg and have a body mass index of = 18 to
= 32 kg/m2
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- History of acute or chronic renal failure, thromboembolism, chronic respiratory
illness, aseptic meningitis syndrome, or recurrent severe headaches or migraines.

- Positive viral serology test for HIV -1/2 antibody, hepatitis B virus surface antigen,
or hepatitis C virus antibody

- Positive viral serology test for SARS-CoV-2 antibodies

- Received any live viral or bacterial vaccinations within 8 weeks

- Evidence of current active infection.

- Known malignancy or a history of malignancy in the past 5 years

- Female subject of childbearing potential or fertile male subject either not using or
not willing to use an acceptable double barrier method of contraception to avoid
pregnancy during the study

Study design
Purpose of the study
Other
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/02/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
9/06/2021
Sample size
Target
Accrual to date
Final
12
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
CMAX Clinical Research - Adelaide
Recruitment postcode(s) [1] 0 0
SA 5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
CSL Behring
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
CSL760 is a human hyperimmune product of the purified gamma immunoglobulin (IgG) fraction of
human plasma containing polyvalent neutralizing antibodies to SARS-CoV-2 (severe acute
respiratory syndrome coronavirus 2). CSL is evaluating CSL760 as a passive immunotherapy for
COVID-19 (Coronavirus Disease 2019).
Trial website
https://clinicaltrials.gov/ct2/show/NCT04638634
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
CSL Innovation Pty Ltd
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04638634